Ligand Pharmaceuticals to Acquire XOMA Royalty for $739M, Boosting Portfolio and Raising 2026 EPS Guidance

summarizeSummary

Ligand Pharmaceuticals announced the acquisition of XOMA Royalty Corporation for $739 million in cash and CVRs, a move expected to be immediately accretive to earnings and significantly expand its royalty portfolio.

check_boxKey Events

• Acquisition Agreement

  Ligand will acquire XOMA Royalty Corporation for approximately $739 million, consisting of $39.00 per share in cash and one non-transferable Contingent Value Right (CVR) per share.

• Financial Impact

  The acquisition is expected to be immediately accretive to Ligand's adjusted EPS, with 2026 guidance raised to $8.50-$9.50 and an anticipated $1.50 per share accretion in 2027.

• Portfolio Expansion

  The deal adds seven new commercial products and over 120 development-stage assets, significantly diversifying and strengthening Ligand's biopharma royalty portfolio.

• Shareholder Support

  Entities affiliated with BVF Partners (owning approximately 44% of XOMA's common stock on an as-converted basis) and XOMA's directors and officers have entered into voting agreements supporting the transaction.

auto_awesomeAnalysis

Ligand Pharmaceuticals is making a significant strategic move by acquiring XOMA Royalty Corporation for $739 million in cash and contingent value rights (CVRs). This acquisition is expected to immediately enhance Ligand's financial performance, as evidenced by the increased 2026 adjusted EPS and revenue guidance. The deal substantially expands Ligand's royalty portfolio, adding seven new commercial products and over 120 development-stage assets, which is crucial for long-term growth and diversification in the biopharma royalty aggregation space. The inclusion of CVRs for XOMA shareholders provides potential upside from ongoing litigation, aligning interests. This transaction is a major catalyst for Ligand, signaling aggressive growth and portfolio strengthening.